Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2018

01-03-2018 | Research Letter

Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors—overlooked and overwhelming? A retrospective case series

Authors: Nino Cristiano Chilelli, Giuseppe Bax, Giulio Bonaldo, Eugenio Ragazzi, Massimo Iafrate, Filiberto Zattoni, Federico Bellavere, Annunziata Lapolla

Published in: Endocrine | Issue 3/2018

Login to get access

Excerpt

As outlined in the latest recommendations for patients with type 2 diabetes (DM2), sodium glucose cotransporter 2 inhibitors (SGLT2i) can be added on treatments with metformin or sulfonylurea plus metformin if glycemic goals are not met [1]. Genital and urinary infections are well-known side effects of SGLT2i, with reported odds ratios in the range of 3.21–5.23, compared with placebo [2, 3]. …
Literature
1.
W.T. Cefalu, M.C. Riddle, SGLT2 inhibitors: the latest “new kids on the block”! Diabetes Care 38(3), 352–354 (2015)CrossRef
2.
D. Li, T. Wang, S. Shen, Z. Fang, Y. Dong, H. Tang, Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes. Metab. Epub ahead of print (2016)
3.
W.T. Cefalu, L.A. Leiter, K.H. Yoon et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382, 941–950 (2013)CrossRef
4.
H. Yamasaki, K. Ogawa, H. Sasaki et al. Prevalence and risk factors of erectile dysfunction in Japanese men with type 2 diabetes. Diabetes Res. Clin. Pract. 66(Suppl 1), S173–S177 (2004)CrossRef
5.
G.N. Collins, G.M. Raab, M. Hehir, B. King, W.M. Garraway, Observer variability and reproducibility of transrectal ultrasound in the measurement of prostatic volume. Ultrasound Med. Biol. 21, 1101 (1995)CrossRef
6.
N. Kebapci, A. Yenilmez, B. Efe, E. Entok, C. Demirustu, Bladder dysfunction in type 2 diabetic patients. Neurourol. Urodyn. 26, 814–819 (2007)CrossRef
7.
S. Geerlings, V. Fonseca, D. Castro-Diaz, J. List, S. Parikh, Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res. Clin. Pract. 103, 373–381 (2014)CrossRef
8.
C.C. Wang, M.B. Chancellor, J.M. Lin, J.H. Hsieh, H.J. Yu, Type 2 diabetes but not metabolic syndrome is associated with an increased risk of lower urinary tract symptoms and erectile dysfunction in men aged <45 years. BJU Int. 105, 1136–1140 (2010)CrossRef
9.
H.J. Song, E.J. Lee, N. Bergstrom, D.H. Kang, D.H. Lee, G. Koh, J.S. Huh, S.D. Kim, S.C. Hong, S.S. Moon, J. Kang, Lower urinary tract symptoms and erectile dysfunction in men with type 2 diabetes mellitus. Int. Neurourol. J. 17, 180–185 (2013)CrossRef
10.
T. Heise, E. Seewaldt-Becker, S. Macha et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes. Metab. 15, 613–621 (2013)CrossRef
11.
S.O. Kim, H.S. Choi, Y.J. Kim et al. Impact of nocturia on health-related quality of life and medical outcomes study sleep score in men. Int. Neurourol. J. 15, 82–86 (2011)CrossRef
12.
P.A. Low, L.M. Benrud-Larson, D.M. Sletten, T.L. Opfer-Gehrking, S.D. Weigand, P.C. O’Brien, G.A. Suarez, P.J. Dyck, Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 27, 2942–2947 (2004)CrossRef
13.
K. Rafiq, Y. Fujisawa, S.J. Sherajee, A. Rahman, A. Sufiun, H. Kobori, H. Koepsell, M. Mogi, M. Horiuchi, A. Nishiyama, Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats. Diabetologia 58, 2885–2898 (2015)CrossRef
Metadata
Title
Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors—overlooked and overwhelming? A retrospective case series
Authors
Nino Cristiano Chilelli
Giuseppe Bax
Giulio Bonaldo
Eugenio Ragazzi
Massimo Iafrate
Filiberto Zattoni
Federico Bellavere
Annunziata Lapolla
Publication date
01-03-2018
Publisher
Springer US
Published in
Endocrine / Issue 3/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1301-x

Other articles of this Issue 3/2018

Endocrine 3/2018 Go to the issue

Original Article

Effects of short-term DHEA intake on hormonal responses in young recreationally trained athletes: modulation by gender

Review

Regulation, signalling and functions of hormonal peptides in pulmonary vascular remodelling during hypoxia

Review

Postpartum glucose intolerance: an updated overview

Clinical Management of Endocrine Diseases

Cantú syndrome with coexisting familial pituitary adenoma

Viewpoint

Particulate matter air pollution: individual choices for improving cardiometabolic well-being

Original Article

Shear wave elastography and Afirma™ gene expression classifier in thyroid nodules with indeterminate cytology: a comparison study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits